Korea's Cosmetic ODM Expansion Race: The New Capacity Arrives in 2027

What is the signal here?

Expansion news from Korea's cosmetic ODM sector arrived all at once in September. Cosmecca Korea disclosed on September 9 that it had decided on a new facility investment of 136 billion won, with an investment period running to December 31, 2030. Combined with its June agreement to acquire the land and buildings of the Ochang plant in Cheongju for 64 billion won, total investment in the Ochang production base comes to 200 billion won. According to reports, the company will build a skincare production plant of some 50,000 square meters of floor area in the Ochang Science Industrial Complex in Cheongju, break ground this month, begin first-phase operation in 2027, and expand equipment in stages through 2030.

Other companies are moving the same way. Cosmax decided in May to put an additional 60.5 billion won into its Pyeongtaek production base, a sum equal to 9.9% of its equity. Its global annual production capacity is reported at around 3.5 billion units, and it is pursuing expansion to about 4 billion units including the start-up of new overseas plants. Kolmar Korea signed an investment agreement with Sejong City to relocate its Beijing plant in China back to Korea, with investment of roughly 173.3 billion won. Annual output at the Sejong site is reported to rise from 450 million units to 890 million units. Export performance sits behind all of this. Korea's cosmetic exports reached $7 billion in the first half of this year, up 27.3% year on year and the highest half-year figure on record, and Cosinkorea reported that exports in early September rose 46.1% led by Europe and North America, putting the combined expansion spending of the three ODM firms at 430 billion won.

These figures should not be read as one block, however. Disclosed investment amounts are plans rather than money already spent, and investment periods and start-up dates differ by company. Capacity figures also mix domestic-site and global bases, which makes simple comparison or addition unreliable. The line that 'domestic capacity, which grew to 1.02 billion units last year, will be expanded a further 10% over existing levels by the end of 2026' is a forecast, not a result. For a brand, the meaningful information is not the headline total but which formats and which lines that capacity opens for, and when.

1. An expansion announcement is 2027 capacity, not today's

The most common misreading is to take expansion news as 'securing production will get easier now.' Even on the reported schedules, Cosmecca's Ochang plant breaks ground this month for first-phase operation in 2027, and Kolmar Korea's Sejong Plant 1 expansion runs through the second half of this year for full operation in the first half of next year. The capacity being announced now is next year's capacity and beyond, and competition for production slots in the fourth quarter of this year and the first half of next year remains exactly as it was.

So what a brand should hold onto at this point is not the scale of expansion but the queue on current lines. If you take a 'yes, we can do it' at the quotation stage and lock your schedule on that, you have no lever left when your production sequence slips after the order goes in. The busier the order book, the more 'when can it be made' has to be settled before 'what will it cost.'

• The expected point at which this formula enters a filling line if ordered now
• Whether that point is confirmed or an estimate subject to other volumes
• Whether an alternative line or specification exists until the expansion completes
• The minimum notice period needed between an initial order and a repeat order

2. What grows is unit count, not a line for your formula

The capacity in these announcements is mostly expressed in units per year—Kolmar Korea's Sejong site going from 450 million to 890 million units, for instance. But the bottleneck in cosmetic production is not total units; it is a line suited to a particular formula and container. More skincare filling capacity does not mean color cosmetics, aerosol or powder lines grow with it.

That is why it is worth noting that Cosmecca's Ochang plant was reported specifically as a skincare production plant. The direction of an expansion is also a signal about which category of orders that company intends to grow. If your product matches that direction, room for negotiation opens later; if it does not, the added capacity belongs to someone else.

The unit to confirm in conversation with a partner, then, is not 'how many hundred million units' but 'how many lines can handle this viscosity, this container and this filling method.' Ask the same question at two or three companies and the ones with real headroom separate quickly from the ones with headroom only in conversation.

3. Confirm the terms for small volumes while capacity is tight

When orders pile up, large volumes generally get the advantage in line allocation. The reports cited here cover each company's investment scale and operating plans; they do not address minimum order quantities or small-batch policies. There is therefore no basis for asserting that MOQs are rising or that small runs are becoming harder.

You can still check, though. A brand starting small is safer getting the minimum order quantity in writing early in discussions, along with the basis on which it applies—per formula or per container—and how long those terms hold. Verbally agreed terms are the first thing to move when lines get crowded.

One more point: while an expansion is under way, an existing plant may be running construction and production at the same time. Cosmax's Pyeongtaek work is reported to have started in June and to run through the end of next month. It is worth asking about schedule variability during periods like that.

4. Read the overseas footprint alongside the domestic build-out

This round is not only about building more plants; it also has the character of rearranging where production happens. Kolmar Korea's decision to move its Beijing plant back to Korea is the clearest example. When a production base shifts from China to Korea, the conditions for China-facing domestic production and for export production can change.

Cosmecca Korea raised its stake in its U.S. ODM subsidiary Englewood Lab from 39% to 66.67% through two tender offers, and in September was reported to be strengthening its grip on the U.S. ODM and packaging business by absorbing the subsidiary. Cosmax likewise includes new overseas plant start-ups in its capacity expansion plans.

For a brand preparing U.S. or European volume, this touches daily work. Even with the same partner, domestic production and local production differ in raw-material sourcing, regulatory handling and lead time. Specifying from the outset which plant a product is made in reduces the retracing needed later when export documentation is prepared.

5. Who grew matters more than the fact that exports grew

Look only at $7 billion in first-half cosmetic exports and the whole market looks healthy. In the detail, though, one line stands out: SME cosmetic exports reached $5.07 billion, up 30.7% year on year. Analysis also notes that while established indie brands such as Medicube, Anua, d'Alba and Beauty of Joseon scaled up, new brands made their mark in Europe, North America and Latin America.

ODM expansion is closer to a consequence of that pattern. As the number of brands grows and turnover speeds up, a manufacturer needs equipment able to absorb repeat orders from many brands rather than one large order from a single brand. Read from the brand side, it means planning your schedule on the assumption that you are not the only one in a hurry.

It is also worth remembering that these figures come from different statistics. Export performance is measured at customs, capacity at the equipment level, and expansion spending at the disclosure level. Rather than tying all three into a single causal story, it keeps judgment cleaner to treat each as a separate reference indicator.

The first question for the brief

Write this on the first line of the brief: which plant, which line, and which month will fill the initial volume of this product? Expansion news is a story about 2027 and later, while production slots for the end of this year and the first half of next year are being allocated to whoever is negotiating now. Rather than waiting for capacity to grow, it is far faster to hand your partner a finalized formula and container specification today and get the line allocation date in writing.